Stem Cell Reports, Volume 3
Supplemental Information

Methylation and Transcripts Expression at the Imprinted GNAS Locus in Human Embryonic and Induced Pluripotent Stem Cells and Their Derivatives

Virginie Grybek, Laetitia Aubry, Stéphanie Maupetit-Méhouas, Catherine Le Stunff, Cécile Denis, Mathilde Girard, Agnès Linglart, and Caroline Silve

Supplemental Information

Legends for supplemental figures

Figure S1: Relative quantitative real-time expression of the five *GNAS* transcripts, Related to Figure 2. A color code is attributed to each fibroblasts (triangle), PSC (circles) and progeny (squares), in order to distinguish expression changes for a given Fibroblast/PSC/Progeny pair at each transcript.Fb: fibroblasts; PSC: pluripotent stem cells; Pro: progenies.

Figure S2: Methylation quantification at the DMRs of *GNAS* comparing PSC, Related to Figure 3. Methylation at each of the four DMRs was similar. Cell cultures, quantification of methylation and statistical analysis were performed as described in the methods section. This figure shows the same PSC data than that presented figure 2, but showing in different columns data for hESC (○) and hiPSC (●), in order to facilitate the comparison between the two types of PSC. The median for each group is indicated by the horizontal line.

Figure S3: Methylation quantification at the four DMRs of *GNAS* in PSC compared to progenies, Related to Figure 4. This figure shows the same data than that presented figure 4. However a color code is attributed to each PSC (circles) and progeny (squares), in order to distinguish methylation changes for a given PSC/Progeny pair at each DMR. PSC: pluripotent stem cells; Pro: progenies.

Figure S4 : Analysis of mono- or bi-allelic expression of *GNAS* transcripts quantified by pyrosequencing, Related to Methods and Figure 5. Pyrograms of the TACAT C/T CTG sequence covering the rs7121 coding polymorphism (T393C) analyzed in PCR products obtained from gDNA (A) and cDNA (B and C) are shown for iPSC90_c17. (A) Heterozygosity at the gDNA level, indicated by 44.7 % and 55.3 % T and C respectively; (B) Biallelic expression of Gsα transcript indicated by 57.5 and 42.5 T and C respectively; (C) Monoallelic expression of *NESP55* transcript indicated by 98.3% and 1.7% T and C respectively. The rs7121polymorphism is indicated in bold letters (C/T). Heterozygosity at the *GNAS* polymorphism rs7121 (T393C) and transcript allelic expression analysis were analyzed as described in the methods section.

Figure S5: Allelic transcript expression in parental fibroblasts, hiPSC and progenies, Related to Figure 5. Panels A and B: Results from parental fibroblasts 4603 and i90 respectively. This figure shows the same data than that presented figure 5. However, results from the two fibroblast lines are presented in different panels in order to distinguish DMR methylation changes between the two cell lines. Fb: fibroblasts; Pro: progenies.

Table S1: primer sequences, CpGs positions and PCR conditions for *GNAS* DMRs amplification and methylation analysis, Related to Methods

Table S2: primer sequences and PCR conditions to analyze the *GNAS* polymorphism rs7121 on genomic DNA and transcript cDNA, Related to Methods




Figure S1, Related to Figure 2




Figure S2, Related to Figure 3




Figure S3, Related to Figure 4




Figure S4, Related to methods and Figure 5




Figure S5, Related to Figure 5

Table S1: Primer sequences, CpGs position and PCR conditions for GNAS DMRs amplification and methylation analysis, Related to methods

PCR	NESP1	NESP2	AS1	AS2	XL1	XL2	АВ
Forward primer	5'AGAGTTTTAG GGAAGGGGAG GA3'	5'GAAGGAGTTT AAGGAGGAGA AGTAG3'	5'GTAGTGGGG TTAAAGGAG3'	5'GTGGGTATTT ATTTTTGGTTA GT3'	5'AGTTTATTTT AAGAGGTTGTT AGAT3'	5'GGGTAGTAG TTTTTGGATGG AGAT3'	5'GGGATATTTG AGAGTTTTGAAA GAA3'
Reverse primer ¹	5'ACTAACCTAA ATCCATAAAAA CAAA3'	5CCATAAAAAC AAAAAAAATCT AAAC3'	5'CTAAACCCAC AAATAAATACC AT3'	5'CTAAACCCAC AAATAAATACC AT3'	5'ACTCCTTCCA TCTCTACTACT 3'	5'CATCTCTACT ACTTCCTCCTC AACTAAA3'	5'AAAAATACAAA ACCTCCCCTAC TC3'
PCR conditions	5 min, 95°C; 55 cycles of (20s, 95°C; 20s, 56°C; 20s, 72°C); 7 min, 72°C	5 min, 95°C; 55 cycles of (30s, 95°C; 30s, 60°C; 30s, 72°C); 7 min, 72°C	5 min, 95°C; 55 cycles of (15s, 95°C; 15s, 56°C; 15s, 72°C); 7 min, 72°C	5 min, 95°C; 55 cycles of (30s, 95°C; 30s, 56°C; 30s, 72°C); 7 min, 72°C	5 min, 95°C; 55 cycles of (30s, 95°C; 30s, 54°C; 30s, 72°C); 7 min, 72°C	15 min, 95°C; 55 cycles of (30s, 95°C; 30s, 60°C; 30s, 72°C); 7 min, 72°C	5 min, 95°C; 55 cycles of (20s, 95°C; 20s, 56°C; 20s, 72°C); 7 min, 72°C
Sequencing primer 1	5'GTTGTAAGT	GTTGTAAGTTAAAGAAGTT3' 5'GGGGTTAAAGGAGTTG3' 5'GTTAATATGGATAGTTTT3'		GATAGTTTT3'	5'AGGGTGTTTA GGTAAG3'		

Sequencing				5'AGGGTGTTTA
primer 2				GGTAAG3'
				57,463,629
		57,426,926		
				57,463,653
	57,415,837	57,426,931	57,429,310	
				57,463,658
CpGs	57,415,840	57,426,935	57,429,312	
	57 445 045	400 040	400 040	57,463,665
position	57,415,845	57,426,942	57,429,319	57 400 070
(Hg19)	F7 44F 047	F7 400 0F0	57 420 224	57,463,679
	57,415,847	57,426,950	57,429,324	57,463,686
	57,415,853	57,426,957	57,429,340	57,403,000
	37,413,033	37,420,937	37,429,340	57,463,693
		57,426,970		07,400,000
		3.,.20,070		57,463,700

The HotStarTaq DNA Polymerase (Qiagen) was used for the amplification of XL-PCR2 and the Platinum Taq DNA Polymerase (Life Technologies) was used for the others PCR

1: For DMR amplification, the reverse primers were biotinylated

Table S2: Primer sequences and PCR conditions to analyze the GNAS polymorphism rs7121 on genomic DNA and transcript cDNA, Related to methods

PCR	gPCR	RT-PCR_NESP	RT-PCR_XL	RT-PCR_AB	RT-PCR_Gs			
Forward primer ¹	5'TGAAAGCAGTACTC	5'CTTCCAAAAAGGGA	5'CGCAGTAAGCTCAT	5'CCTTGCGTGTGAGT	5'CGTGAGGCCAACA			
	CTAACTGACA3'	CCCATC3'	CGACAA3'	GCACCT3'	AAAAGAT3'			
Reverse primer ¹	5'TGTTCCTATATGGA	5'ATGGCAGTCACATCGTTGAA3'						
p	CACTGTGCT3'							
	5min, 95°C; 35 cycles							
PCR conditions	of (30s, 95°C; 30s,	of (30s, 95°C; 30s, 5min, 95°C; 40 cycles of (30s, 95°C; 30s, 58°C; 30s, 72°C); 7 min, 72°C; hold 4°C						
	60°C; 30s, 72°C); 7							
	min, 72°C ; hold 4°C							
Forward 5'GAGAACCAGTTCAGAGT 3'								
Sequencing primer ²								
Reverse	5'GTCAGGCACGTTCATCACACTC 3'							
Sequencing primer ²								

- 1. Amplifications were performed for each product with either the forward or reverse primer being biotinylated
- 2. As a function of the biotinylated primer used for cDNA amplification, either the forward or reverse sequencing primer was biotinylated